Rachel Hevey

Dr. Rachel Hevey

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 December 2018 in Chemistry – A European Journal
Verified
Journal Article
Closed access
PDF file
PFPriska Frei
Priska Frei
RHRachel Hevey
Rachel Hevey
BEBeat Ernst
Beat Ernst

11 April 2019 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
RHRachel Hevey
Rachel Hevey
Carbohydrates are a structurally-diverse group of natural products which play an important role in numerous biological processes, including immune regulation, infection, and cancer metastasis. Many diseases have been correlated with changes in the composition of cell-surface glycans, highlighting their potential as a therapeutic target. Unfortunately, native carbohydrates suffer from inherently weak binding affinities and poor pharmacokinetic properties. To enhance their usefulness as drug candidates, ‘glycomimetics’ have been developed: more drug-like compounds which mimic the structure and function of native carbohydrates. Approaches to improve binding affinities (e.g., deoxygenation, pre-organization) and pharmacokinetic properties (e.g., limiting metabolic degradation, improving permeability) have been highlighted in this review, accompanied by relevant examples. By utilizing these strategies, high-affinity ligands with optimized properties can be rationally designed and used to address therapies for novel carbohydrate-binding targets.

6 June 2022 in Nature Chemical Biology
Verified
Journal Article
Closed access
PDF file
JTJulie Takagi
Julie Takagi
KAKazuhiro Aoki
Kazuhiro Aoki
BTBradley S. Turner
Bradley S. Turner
SLSabrina Lamont
Sabrina Lamont
SLSylvain Lehoux
Sylvain Lehoux
KRKatharina Ribbeck
Katharina Ribbeck

9 September 2020 in Chemistry – A European Journal
Verified
Journal Article
Closed access
PDF file
RHRachel Hevey
Rachel Hevey

28 July 2019 in Biomimetics
Verified
Journal Article
Open access
PDF file
RHRachel Hevey
Rachel Hevey
The aberrant presentation of carbohydrates has been linked to a number of diseases, such as cancer metastasis and immune dysregulation. These altered glycan structures represent a target for novel therapies by modulating their associated interactions with neighboring cells and molecules. Although these interactions are highly specific, native carbohydrates are characterized by very low affinities and inherently poor pharmacokinetic properties. Glycomimetic compounds, which mimic the structure and function of native glycans, have been successful in producing molecules with improved pharmacokinetic (PK) and pharmacodynamic (PD) features. Several strategies have been developed for glycomimetic design such as ligand pre-organization or reducing polar surface area. A related approach to developing glycomimetics relies on the bioisosteric replacement of carbohydrate functional groups. These changes can offer improvements to both binding affinity (e.g., reduced desolvation costs, enhanced metal chelation) and pharmacokinetic parameters (e.g., improved oral bioavailability). Several examples of bioisosteric modifications to carbohydrates have been reported; this review aims to consolidate them and presents different possibilities for enhancing core interactions in glycomimetics.

15 March 2012 in Future Medicinal Chemistry
Verified
Journal Article
Closed access
RHRachel Hevey
Rachel Hevey
CLChang-Chun Ling
Chang-Chun Ling
Cancer cells can often be distinguished from healthy cells by the expression of unique carbohydrate sequences decorating the cell surface as a result of aberrant glycosyltransferase activity occurring within the cell; these unusual carbohydrates can be used as valuable immunological targets in modern vaccine designs to raise carbohydrate-specific antibodies. Many tumor antigens (e.g., GM2, Le(y), globo H, sialyl Tn and TF) have been identified to date in a variety of cancers. Unfortunately, carbohydrates alone evoke poor immunogenicity, owing to their lack of ability in inducing T-cell-dependent immune responses. In order to enhance their immunogenicity and promote long-lasting immune responses, carbohydrates are often chemically modified to link to an immunogenic protein or peptide fragment for eliciting T-cell-dependent responses. This review will present a summary of efforts and advancements made to date on creating carbohydrate-based anticancer vaccines, and will include novel approaches to overcoming the poor immunogenicity of carbohydrate-based vaccines.